z-logo
open-access-imgOpen Access
Protein Losing Enteropathy after Fontan Surgery – Clinical and Diagnostical Aspects
Author(s) -
Attila Tárnok,
József Bocsi,
Dominik Lenz,
Jan Janoušek
Publication year - 2007
Publication title -
transfusion medicine and hemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.971
H-Index - 39
eISSN - 1660-3818
pISSN - 1660-3796
DOI - 10.1159/000101373
Subject(s) - medicine , protein losing enteropathy , hypoalbuminemia , hypoproteinemia , enteropathy , ascites , gastroenterology , central venous pressure , fontan procedure , heart failure , cardiology , surgery , ventricle , blood pressure , heart rate , disease
Protein losing enteropathy (PLE) is the massive enteric loss of serum protein. PLE may appear in several diseases associated with intestinal mucous membrane damages with or without infection. PLE is mostly associated with total cavopulmonary connection (TCPC) or Fontan-type circulation in patients with a functionally univentricular heart. TCPC is performed at an age of about 2 years or older and has a high survival rate of >90%. Time of PLE onset after TCPC is variable, the exact etiology is still unclear. Increased central venous pressure due to the absence of a subpulmonary ventricle may be a main reason for PLE, affecting 2-15% of the patients with a survival rate of 40% at 5 years and 20% at 10 years. Also immunological reasons for PLE are suspected. Major clinical signs are edemas, ascites, pleural effusion, diarrhea, malnutrition, fatigue, weight loss, and reduced physical development. The most impaired laboratory signs are elevated fecal α1-antitrypsin and α1-antitrypsin clearance, hypoproteinemia (hypoalbuminemia, hypo-γ-globulinemia), lymphopenia (selective T helper cell loss) and secondary lymphangiectasia. Therapy considerations should have the aim to decrease central venous pressure to improve hemodynamics. Medical treatment consists of substitution of e.g. albumin, γ-globulin, glucocorticoid, heparin or calcium, but still >60% of the patients remain symptomatic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom